Atlas Trials

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

Clinical trial NCT04892277 · RECRUITING

Trial details

NCT number
NCT04892277
Sponsor
Mayo Clinic
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRecurrent Transformed Chronic Lymphocytic LeukemiaRefractory B-Cell Non-Hodgkin LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Small Lymphocytic LymphomaRefractory Transformed Chronic Lymphocytic Leukemia
Start date
2022-10-03
Primary completion
2028-03-27
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.